Transgene-Biotek (3)
| Date | Circular | Tags | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BSE announces changes to the Long Term ASM Framework effective March 09, 2026, including 2 new securities shortlisted, 6 securities moved to … | |||||||||||||||
BSE announces changes to the Long Term ASM Framework effective March 09, 2026, including 2 new securities shortlisted, 6 securities moved to lower ASM stages, and 25 securities moving out of the framework.
| |||||||||||||||
BSE announces securities being added to, moved within, and removed from the Long Term Additional Surveillance Measure (LT-ASM) framework … | |||||||||||||||
BSE announces securities being added to, moved within, and removed from the Long Term Additional Surveillance Measure (LT-ASM) framework effective March 09, 2026.
| |||||||||||||||
SEBI issues prohibitory order under Recovery Certificate No. 6156 of 2022 against Sampath Kumar Meesala (PAN: AIIPM9512D) in connection with … | |||||||||||||||
SEBI issues prohibitory order under Recovery Certificate No. 6156 of 2022 against Sampath Kumar Meesala (PAN: AIIPM9512D) in connection with Transgene Biotek Limited.
| |||||||||||||||